431 related articles for article (PubMed ID: 15878443)
21. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
22. Eight-year (2002-2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries.
Ross JE; Farrell DJ; Mendes RE; Sader HS; Jones RN
J Chemother; 2011 Apr; 23(2):71-6. PubMed ID: 21571621
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
Fritsche TR; Sader HS; Stillwell MG; Jones RN
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
Sader HS; Streit JM; Fritsche TR; Jones RN
Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
[TBL] [Abstract][Full Text] [Related]
25. Linezolid in vitro: mechanism and antibacterial spectrum.
Livermore DM
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii9-16. PubMed ID: 12730138
[TBL] [Abstract][Full Text] [Related]
26. A multicenter evaluation of linezolid antimicrobial activity in North America.
Ballow CH; Jones RN; Biedenbach DJ;
Diagn Microbiol Infect Dis; 2002 May; 43(1):75-83. PubMed ID: 12052632
[TBL] [Abstract][Full Text] [Related]
27. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
Streit JM; Jones RN; Sader HS; Fritsche TR
Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
[TBL] [Abstract][Full Text] [Related]
28. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers).
Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2012 Sep; 74(1):54-61. PubMed ID: 22704791
[TBL] [Abstract][Full Text] [Related]
29. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
Zhanel GG; DeCorby M; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; Mulvey MR; Hoban DJ;
Diagn Microbiol Infect Dis; 2008 Sep; 62(1):67-80. PubMed ID: 18513913
[TBL] [Abstract][Full Text] [Related]
31. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe).
Bolmstrom A; Ballow CH; Qwarnstrom A; Biedenbach DJ; Jones RN
Clin Microbiol Infect; 2002 Dec; 8(12):791-800. PubMed ID: 12519352
[TBL] [Abstract][Full Text] [Related]
32. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793
[TBL] [Abstract][Full Text] [Related]
33. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.
Jones RN; Ballow CH; Biedenbach DJ;
Diagn Microbiol Infect Dis; 2001; 40(1-2):59-66. PubMed ID: 11448565
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.
Draghi DC; Sheehan DJ; Hogan P; Sahm DF
Antimicrob Agents Chemother; 2005 Dec; 49(12):5024-32. PubMed ID: 16304168
[TBL] [Abstract][Full Text] [Related]
35. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
Johnson AP; Mushtaq S; Warner M; Livermore DM
Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
[TBL] [Abstract][Full Text] [Related]
36. Nosocomial outbreak of linezolid-resistant Enterococcus faecalis infection in a tertiary care hospital.
Gómez-Gil R; Romero-Gómez MP; García-Arias A; Ubeda MG; Busselo MS; Cisterna R; Gutiérrez-Altés A; Mingorance J
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):175-9. PubMed ID: 19717261
[TBL] [Abstract][Full Text] [Related]
37. [Sensitivity of methicillin resistant staphylococci to linezolid and some other antimicrobial agents].
Ertek M; Yazgi H; Aktaş E; Ayyildiz A; Parlak M
Mikrobiyol Bul; 2003 Oct; 37(4):235-40. PubMed ID: 14748259
[TBL] [Abstract][Full Text] [Related]
38. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.
Flamm RK; Mendes RE; Ross JE; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2013 Jun; 76(2):206-13. PubMed ID: 23478031
[TBL] [Abstract][Full Text] [Related]
39. [In vitro activity of linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus].
Pérez L; Alarcón T; Jiménez S; de Las Cuevas MC; López-Brea S
Rev Esp Quimioter; 2001 Mar; 14(1):47-50. PubMed ID: 11376349
[TBL] [Abstract][Full Text] [Related]
40. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
Aktaş G; Bozdoğan B; Derbentli S
Mikrobiyol Bul; 2012 Jul; 46(3):359-65. PubMed ID: 22951648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
